Brehler R
Klinik für Hautkrankheiten, Ambulanz für Allergologie, Berufsdermatologie und Umweltmedizin, Universitätsklinikum Münster, Von-Esmarch-Str. 58, 48149, Münster, Deutschland.
Hautarzt. 2017 Apr;68(4):292-296. doi: 10.1007/s00105-017-3935-2.
It is estimated that only 5% of all patients who can principally benefit from specific immunotherapy (SIT) undergo this treatment. SIT represents the only curative treatment for allergic disorders and efficacy has been demonstrated with various allergens. There is an urgent demand for the development of safe preparations with enhanced efficacy achievable by only a few administrations. Adjuvants are pharmacological or immunological acting molecules modifying the specific immunological response to allergens. In vaccine technology, adjuvants are broadly used to enhance immunogenicity of highly purified antigens with low immune stimulating activity. Adjuvants may target to a retarded allergen release, a modulation of the immune system, or can be used as vector systems to transport allergens and adjuvants effectively to target cells.
据估计，在所有主要可从特异性免疫疗法（SIT）中获益的患者中，只有5%接受了这种治疗。SIT是过敏性疾病的唯一治愈性疗法，并且已在多种变应原上证实了其疗效。迫切需要开发仅通过少量给药就能实现增强疗效的安全制剂。佐剂是改变对变应原的特异性免疫反应的药理学或免疫学作用分子。在疫苗技术中，佐剂被广泛用于增强低免疫刺激活性的高度纯化抗原的免疫原性。佐剂可针对延缓变应原释放、调节免疫系统，或用作载体系统以将变应原和佐剂有效地转运至靶细胞。
